Anderson to lead Pfizer’s vaccine R&D

Annaliesa Anderson will lead vaccine R&D at Pfizer Inc. (NYSE:PFE) as SVP and head of vaccine R&D from Aug. 1, succeeding Kathrin Jansen whose retirement was announced last month. Anderson is a 15-year veteran of Pfizer who most recently served as VP and CSO for bacterial research and hospital with the company, which she joined in 2007 via Wyeth. Prior to that, she worked in bacterial vaccine development roles at Merck & Co. Inc. (NYSE:MRK). 

Luca Scavo will resign as CFO from Evelo Biosciences Inc. (NASDAQ:EVLO), an inflammatory disease play, on June 3. President and CEO Balkrishan “Simba” Gill will become the interim principal financial officer until a successor is named...